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Abstract
Background: Chikungunya virus (CHIKV) is a re-emerging arbovirus associated with febrile illness often accompanied by
rash and arthralgia that may persist for several years. Outbreaks are associated with high morbidity and create a public
health challenge for countries affected. Recent outbreaks have occurred in both Europe and the Americas, suggesting
CHIKV may continue to spread. Despite the sustained threat of the virus, there is no approved vaccine or antiviral therapy
against CHIKV. Therefore, it is critical to develop a vaccine that is both well tolerated and highly protective.
Methodology/Principal Findings: In this study, we describe the construction and characterization of a modified Vaccinia
virus Ankara (MVA) virus expressing CHIKV E3 and E2 proteins (MVA-CHIK) that protected several mouse models from
challenge with CHIKV. In particular, BALB/c mice were completely protected against viremia upon challenge with CHIKV
after two doses of MVA-CHIK. Additionally, A129 mice (deficient in IFNa/b) were protected from viremia, footpad swelling,
and mortality. While high anti-virus antibodies were elicited, low or undetectable levels of neutralizing antibodies were
produced in both mouse models. However, passive transfer of MVA-CHIK immune serum to naı¨ve mice did not protect
against mortality, suggesting that antibodies may not be the main effectors of protection afforded by MVA-CHIK.
Furthermore, depletion of CD4+, but not CD8+ T-cells from vaccinated mice resulted in 100% mortality, implicating the
indispensable role of CD4+ T-cells in the protection afforded by MVA-CHIK.
Conclusions/Significance: The results presented herein demonstrate the potential of MVA to effectively express CHIKV E3-
E2 proteins and generate protective immune responses. Our findings challenge the assumption that only neutralizing
antibodies are effective in providing protection against CHIKV, and provides a framework for the development of novel,
more effective vaccine strategies to combat CHIKV.
Citation: Weger-Lucarelli J, Chu H, Aliota MT, Partidos CD, Osorio JE (2014) A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in
Mice. PLoS Negl Trop Dis 8(7): e2970. doi:10.1371/journal.pntd.0002970
Editor: Ann M. Powers, Centers for Disease Control and Prevention, United States of America
Received January 15, 2014; Accepted May 13, 2014; Published July 24, 2014
Copyright:  2014 Weger-Lucarelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grant #AI093491-02. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist. Authors HC and CDP are employees of Takeda, Inc. This does not alter our
adherence to all PLOS policies on sharing data and materials.
* Email: osorio@svm.vetmed.wisc.edu
Introduction
Chikungunya virus (CHIKV; Togaviridae, Alphavirus), the
etiologic agent of Chikungunya fever is an emerging pathogen that
has recently caused several severe outbreaks throughout Africa
and Southeast Asia [1–3]. Large outbreaks have occurred on La
Re´union island (an overseas department of France), Mauritius, Sri
Lanka, and India, among others [4]. In addition, autochthonous
transmission has been seen in Europe, with outbreaks occurring in
both Italy and mainland France [5], suggesting temperate climates
can support virus transmission. Furthermore, as of January 2014,
the European Centre for Disease Control has confirmed 70 cases
of CHIKV on the Caribbean islands of St. Martin, Martinique,
Guadeloupe, and Saint Barthelemy, with many more suspected,
indicating spread to continental America is possible. CHIKV is
transmitted to humans by Aedes aegypti and Aedes albopictus
mosquitoes, the latter of which has been an important vector in
many of the recent outbreaks due to mutations in the envelope
genes of the virus that allow for more efficient transmission [6–9].
CHIKV causes a dengue-like illness associated with fever, rash
and joint pain and was first described in modern day Tanzania in
1952 [10]. The term Chikungunya is derived from the Makonde
word meaning ‘‘that which bends up’’ and describes the posture of
an infected individual [11]. Recently, the U.S. Army developed a
live-attenuated vaccine candidate, called CHIK 181/clone 25 or
181/25, but it caused transient arthralgia in a small number of
volunteers during phase II clinical trials [12,13]. Experimental
subunit [14], recombinant viruses [15–17], and VLP [18] based
vaccines have also been described which are currently at various
stages of preclinical or clinical development, however there
currently are no licensed vaccines or antiviral treatments available
for CHIKV.
An alternative approach for developing CHIKV vaccines is the
use of viral vectors. A complex adenovirus expressing the complete
CHIKV structural poly-protein has been described and was shown
to be immunogenic and protective in mice [19]. However, safety
concerns regarding adenovirus based-vectors may limit this
approach [20]. In contrast, Modified Vaccinia virus Ankara
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(MVA) has been tested in over 120,000 humans and was proven to
be highly safe and effective in protecting against smallpox [21,22].
MVA was attenuated by over 500 passages of Vaccinia virus
(VACV) in chicken embryo fibroblasts (CEFs), which resulted in
large deletions of its genome that restricted its host-range [23,24].
During passaging, MVA lost the ability to productively infect
mammalian cells, leading to abortive replication [25]. VACV,
which is far more reactogenic than MVA [26,27], has been used
previously against other alphaviruses, namely Sindbis and
Venezuelan equine encephalitis (VEEV) viruses, providing robust
immunity against the latter, suggesting poxviruses as suitable
vectors against alphaviruses [28–33]. Despite the presence of high
levels of neutralizing antibodies elicited by most of the VACV
vectored VEEV vaccine candidates, they were ineffective in
providing protection against airborne infection, suggesting they
were unable to elicit a sufficient T cell mediated immune response,
which has been shown to be critical for protection against lethal
VEEV encephalitis [34,35]. MVA, like its parent virus VACV, has
been extensively tested as a vaccine vector, expressing viral,
bacterial or parasite antigens and has been shown to induce both
humoral and cell-mediated protective immune responses [25,36–
42]. Furthermore, MVA can be delivered effectively by different
routes and has much greater stability than most other live virus
based vaccine approaches [43]. Additionally, because MVA
undergoes only abortive replication in mammalian cells, vector
stability is not a problem as only one infection cycle occurs
[25].Therefore, an MVA vectored CHIKV vaccine would be an
attractive option for resource-limited countries, where the majority
of CHIKV infections occur. Additionally, Volz and Sutter (2013)
have targeted MVA as an ideal vector for safe next generation
vaccines, with CHIKV being mentioned specifically as an
attractive candidate pathogen [44]. Furthermore, Garcia-Arriaza
et al. (2014) successfully used MVA for expression of the entire
CHIKV structural protein as a vaccine candidate, indicating
MVA can provide effective immunity against this virus [45].
In this report, we describe the construction and immunological
evaluation of an MVA-based CHIKV candidate vaccine based on
the E3-E2 proteins. The vaccine was tested in two mouse models-
one immunocompetent and the other lacking a/b interferon
signaling (A129)- and was uniformly protective. Mice deficient in
a/b interferon signaling have been used for many viruses and
have been shown repeatedly to be a good model for CHIKV,
providing many similarities to human infection [46–48]. Complete
protection against mortality was provided when MVA-CHIK was
administered in a prime-boost regimen. In addition, it provided
80% protection against mortality in this highly immunocompro-
mised mouse model after only 11 days post-vaccination. Surpris-
ingly, while playing a role, neutralizing antibodies did not appear
to be necessary for protection against CHIKV, contrary to other
recent reports [49,50]. Most importantly, depletion of CD4+ T
cells in vaccinated mice resulted in loss of protection, with 100%
succumbing to infection upon challenge with wild-type CHIKV,
indicating an indispensable role of MVA-CHIK immune CD4+ T
cells in protection.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Labora-
tory Animals of the National Institutes of Health. The IACUC
protocol (Protocol #V01380) was approved by the Institutional
Animal Care and Use Committees of the University of Wisconsin.
Cell culture and viruses
African Green Monkey kidney cells (Vero, ATCC #CCL-81)
and baby hamster kidney cells (BHK-21, ATCC # CCL-10) cells
were maintained in Dulbecco’s modified Eagle medium (DMEM;
Gibco, Carlsbad, CA) supplemented with 5% fetal bovine serum
(FBS), 100 U/ml of penicillin, 100 mg/ml of streptomycin, and
2.5 mg/ml amphotericin B, and incubated at 37uC in 5% CO2.
Chicken embryo fibroblasts (CEFs) were obtained from Charles
River (Charles River Laboratories International, Inc., Wilming-
ton, MA) and maintained in OptiMEM (Invitrogen, Carlsbad,
CA) supplemented with 10% FBS under the same conditions.
Chikungunya virus strain La Reunion (CHIKV-LR; GenBank:
DQ443544.2) was used for both the construction of recombinant
poxviruses and challenge experiments. The virus was kindly
provided by Dr. Scott Weaver (University of Texas Medical
Branch, Galveston, Texas). The CHIK-IRES vaccine candidate
has been previously described [51] and was used in this study as a
positive control. Briefly, the vaccine was constructed by replacing
the subgenomic promoter in a cDNA CHIKV clone with an
internal ribosome entry site from encephalomyocarditis virus
(EMCV-IRES) and has shown to be effective and safe in mice [51]
and non-human primates [52]. The MVA virus used in these
studies was obtained through BEI Resources (NIAID, NIH,ref #
NR-727). A recombinant MVA virus expressing GFP (herein
called MVA-GFP) was based on the wild-type MVA and its
construction has been previously described [37,53].
Construction of recombinant MVA vaccines
For the production of recombinant MVA vaccines, the CHIKV
E2 and E3 genes (hereafter called p62) were PCR amplified using
Phusion High-Fidelity DNA polymerase (New England Biolabs,
Ipswich, MA) and cloned into a specially modified poxvirus
transfer vector, pI2-Red [37]. E2 was chosen because it has been
previously demonstrated that most neutralizing antibodies mapped
to epitopes in this region [49,54,55]. E3 has not been strongly
associated with protection; however, it was included to allow
proper folding of the E2 protein [56]. The expression of p62 was
controlled by a synthetic early/late Vaccinia virus promoter and
used the Vaccinia virus transcription terminator, which have been
previously described [57]. The vector used in this study contained
flanking sequences that when transfected into MVA-GFP infected
cells can recombine into the Deletion III region of the viral
Author Summary
Chikungunya virus (CHIKV) has recently re-emerged from
Africa to cause disease outbreaks in Asia, Europe, and
more recently the Caribbean. The virus is transmitted by
Aedes mosquitoes and causes a disease that is character-
ized by high fever and incapacitating joint pain that can
cause great personal and economic loss. At present, no
approved vaccine or antivirals are approved against CHIKV.
In this study, we developed a novel CHIKV vaccine that is
vectored by Modified Vaccinia virus Ankara (MVA), an
attenuated vaccine vector which has been shown to be
safe in humans and induce a strong immune response. The
vaccine expresses the E3 and E2 proteins of CHIKV, the
latter of which is thought to be the main mediator of
protection. The vaccine was effective in two mouse models
and protected against all markers of disease tested despite
the absence of high levels of neutralizing antibodies, the
gold standard of protection. Depletion of CD4+ T cells from
vaccinated mice resulted in loss of protection, implicating
these cells in the protection induced by the vaccine.
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genome [58]. This vector contains DsRed under the control of a
late p11 promoter to allow for visual based selection and permits
an easy distinction between recombinant (red) and wild-type
(green) viruses (Fig. 1A).
Recombinant MVA-CHIK viruses were generated as described
previously [59,60]. Briefly, CEFs were seeded into six-well plates
the day before transfection and then infected at a multiplicity of
infection (MOI) of 0.05 PFU/cell for 1.5–2 hours with MVA-
GFP. Cells were then washed with 16 PBS and transfected with
appropriate transfer vectors using FuGENE HD (Roche Diagnos-
tics, Indianapolis, IN) following manufacturer’s protocol. Cells
were monitored for the presence of red fluorescence 24 hours after
transfection. At 48–72 h post-transfection, monolayers were
harvested, centrifuged at 5006g for 5 min at 4uC and cells
disrupted by freeze–thaw (3 times) followed by sonication (2 times
for 15 s using a cup sonicator). The disrupted cell extracts
containing recombinant viruses expressing DsRed were plated
onto fresh CEF cells and overlaid with 0.8% agarose. After 48–
72 h, recombinant virus-generated plaques were detected by
observing fluorescence and picked into 300 mL media with a sterile
filter pipette tip. The cell/virus samples were subjected to freeze
thaw and sonication (as described above) and plated to continue
passaging. Plaques were passaged until no wild-type (GFP
expressing) virus was observed at which point PCR was performed
to confirm the presence of only recombinant virus [61]. High titer
virus stocks were prepared from PCR positive cultures and
recombinant MVA-CHIK viruses were further characterized.
PCR analysis was performed on final virus stocks to ensure genetic
homogeneity and stability. DNA was extracted using the quick-
gDNA Miniprep kit from Zymo Research per manufacturer’s
instructions (Zymo Research, Irvine, CA). PCR was then
performed using Phusion polymerase with deletion III specific
primers (Forward 59-atgcggcacctctcttaa-39, Reverse 59-tgggctcctta-
taccaagca- 39).
In vitro characterization of recombinant MVA-CHIK
vaccines
Western blot analyses were used to determine the in vitro
expression patterns of MVA-CHIK constructs. For this purpose,
BHK-21 cells were seeded at 3.06105 cells/well into six-well plates
and 24 hours (hr) later infected at an MOI of 5 PFU/cell in
OptiMEM in the absence of FBS. At 24 hr after infection, cells
were harvested and lysed using Radio-Immunoprecipitation Assay
buffer (RIPA; 150 mM NaCl, 1.0% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) at 4uC for
30 minutes (min) under gentle agitation. Lysates were then
centrifuged for 20 min at 12,000 rpm and supernatant was
collected for further analysis. Supernatants were diluted into 26
Laemmli buffer (Bio-Rad, Richmond, CA), heated at 95uC for
5 min and 50 mL were loaded into a Bio-Rad 4–20% precast
gel. Gels were transferred to a nitrocellulose membrane using
Trans-Blot Turbo Blotting System following manufacturer’s
instructions. Polyclonal serum obtained from specific-pathogen-
free (SPF) rabbits inoculated with a vaccine strain of CHIKV was
used to probe blots at a dilution of 1:5000 and developed using
BCIP/NBT alkaline phosphatase system (Bio-Rad).
BHK-21 cells were used for immunocytochemistry (ICC)
experiments. One day prior to infection, 26105 cells were plated
onto glass coverslips, which had been placed inside of 24 well
tissue culture plates. The following day, the cells were infected at
an MOI of 10 PFU/cell. Infection was allowed to progress for
24 hrs and then fixed using 2% paraformaldehyde (PFA) solution
in phosphate buffer. For permeabilization, cells were treated with
0.5% Triton X-100 for 10 min at 4uC, followed by 50 mM NH4Cl
in PBS for 10 min at room temperature (RT), and then blocked
with PBS containing 10% bovine serum albumin (BSA) for 3 to
4 hr at RT. Cells were then incubated overnight at 4uC with a
1:1000 dilution of anti-CHIKV polyclonal rabbit serum. Cells
were subsequently washed three times with PBS containing 0.05%
Tween and then incubated with a 1:2000 dilution of anti-rabbit
IgG Alexafluor-488 for 45 min at RT. Cells were mounted using
Vectashield mounting medium (Vector Laboratories). Images were
acquired using an Evos microscope with attached camera.
ELISAs were performed as described by Brewoo et al., 2010
[37]. Briefly, 96-well ELISA plates were coated with purified
CHIKV (0.5 mg in 100 mL carbonate buffer, pH 9.6 per well) at
4uC overnight. Coated plates were washed twice with 0.05%
Tween-20 in PBS (washing buffer) and incubated with blocking
buffer (1% BSA in PBS) at RT for 1 hr. Serum samples then were
serially diluted from 1:100–1:12,800 in ELISA diluent (0.1% BSA
in washing buffer) and added in triplicate to the prepared ELISA
plates and plates were incubated at RT for 1 hr. Known negative
(uninoculated) and positive serum samples from mice inoculated
with CHIK-IRES from previous studies were used as controls.
After washing, 100 mL per well of a 1:10,000 dilution of
horseradish peroxidase (HRP)-conjugated rabbit anti-mouse
IgM+G (Abcam Inc, Cambridge, MA) was added to each well
and incubated at RT for 1 hr. Plates were washed, and 100 mL per
well of tetra-methyl-benzidine (TMB) chromogen (Sigma, St
Louis, MO) was added to each well and incubated in the dark
for 5 min. The reaction was then stopped by adding 100 mL per
well of 2 mM H2S04. Colorimetry was measured using an ELx800
absorbance microplate reader (BioTek, Winooski, VT) at test
wavelength of 450 nm and a reference wavelength of 630 nm.
The highest dilution that was positive (exceeded the mean of
known negative serum samples plus three standard deviations) was
considered the endpoint, and its reciprocal value was recorded as
the titer.
Animal experiments
Groups of four- to six-week-old female BALB/c mice (Harlan
Sprague Dawley, Indianapolis, IN) or six- to ten-week-old mixed
Figure 1. Generation and characterization of candidate MVA-CHIK vaccine virus. Diagram of the MVA-GFP genome and transfer vector
used for homologous recombination for creation of MVA-CHIK. The different areas where deletion occurred in the vaccinia virus genome to create
MVA are shown. MVA-CHIK was created by transfecting the plasmid containing CHIKV p62 under control of a se/l promoter which also expressed
dsRed2 under control of a p11 promoter. This plasmid contains flanking regions to deletion III (DelIII) which is where the recombinant gene was
inserted into the genome with a fluorescent marker (A). PCR analysis of the DelIII region. Viral DNA was extracted from purified, final virus stocks of
MVA-CHIK, MVA-GFP and MVA-WT. PCR was performed using primers specific for the DelIII flanking regions. A DNA ladder is included for comparison
of size (B). Monolayers of CEF cells were infected with recombinant MVA-CHIK viruses at MOI of 5 or 10 PFU/cell for Western Blot or Immunostaining,
respectively. After 24 h post infection, cells were harvested and subjected to SDS-PAGE followed by western blot analysis (C) or fixed with 2% PFA as
described in the methods. Both the cellular pellet and supernatant were analyzed for expression of CHIKV E3/E2. The order is the same for both and is
as follows, wild-type CHIKV (1), MVA-CHIK (2), MVA-GFP (3), and mock infected cells (4). Following fixation, cells for immunostaining were either
allowed to remain intact or permeabilized with triton X-100 (D). Anti-CHIKV polyclonal rabbit was used for primary staining for both assays. Green
represents CHIKV E2 positive cells, red is dsRed protein produced by the virus and blue is nuclear staining with Hoechst.
doi:10.1371/journal.pntd.0002970.g001
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gender a/b interferon signaling deficient mice (A129) received
either primary only or primary and booster immunizations (28
days apart) with each vaccine candidate via intradermal (i.d.)
injection into the hind, left footpad. A dose of 16107 TCID50 units
in 50 mL was used for all MVA vaccinations. The dose chosen is
either lower than or consistent with many previous reports of
MVA vectored vaccines [62–64]. Negative control groups were
immunized with MVA-GFP at the same dose. As a positive
control, mice were vaccinated with experimental control vaccine
virus CHIK-IRES [17] at a dose of 104 TCID50 units. At either 11
days post-prime or two weeks post-boost (where applicable), all
animals were challenged with wild-type CHIKV-LR by i.d.
inoculation of 104 (BALB/c) or 102 (A129) TCID50 units in 50 mL
into the hind, left footpad. Mice were bled prior to boost and prior
to challenge following vaccination to monitor levels of neutralizing
and anti-virus antibodies. Passive transfer studies were performed
using A129 mice as previously described [37]. Briefly, serum was
collected from vaccinated BALB/c or A129 mice and equal
volumes from each sample were used to create a pool of sera for
each mouse strain separately. 100 mL (BALB/c) or 200 mL (A129)
of this inoculum were then injected into naive mice intraperito-
neally (i.p.). Serum from CHIK-IRES vaccinated A129 mice
(100 mL) was used as a positive control. 24 hours after passive
transfer, mice were challenged in the same manner as described
above. Following challenge, mice were bled three days consecu-
tively to monitor viremia via the maxillary vein. With the
exception of the BALB/c experiment, all animal experiments
were repeated at least once, with similar results.
In vivo depletion of T-cells
For depletion studies, groups of six- to ten-week-old A129 mice
(n = 5), were vaccinated i.d. with 107 TCID50 units of MVA-
CHIK on day 0 and boosted day 28. On days 39 and 41 post
priming, immune mice were treated i.p. with 100 mg of anti-CD4
mAb (GK1.5) or 250 mg of anti-CD8a mAb (2.43) (Bio X Cell).
Control groups included untreated immune and non-immune
animals. Each treatment group was challenged i.d. with 500
TCID50 units of CHIKV-LR three days later. Mice were further
treated with depleting antibodies 3, 7 and 10 days post-challenge.
The depletion efficiency in PBMCs on the day of infection was
more than 99% for both T cell subsets as assessed by flow
cytometry by staining with anti-mouse CD4 FITC (RM4-5), anti-
mouse CD8a PerCP (53–6.7) mAbs (from BD Bioscience) (data not
shown). Mice were monitored for morbidity and mortality for two
weeks.
Histopathology
Histopathology was performed on tissues collected from A129
mice 7 days post infection (d.p.i.). Footpad and leg tissues were
severed from euthanized mice, cut in half to expose the tissues, and
fixed in 4% buffered PFA for two days. Hind limbs were then
decalcified in 4% PFA containing 14% EDTA for 3–4 weeks,
changing decalcification solution weekly. Tissues were paraffin
embedded, sectioned and stained with hematoxylin and eosin
(H&E). Pictures were taken using a Sony NEX-5N camera
attached to a Nikon microscope.
Virus quantification and serology
Blood samples collected from mice following challenge were
used to assess viremia. Viremia was assessed via end point dilutions
in 96 well plates seeded with Vero cells (seeded the night before at
26104 cells/well) and was expressed as tissue culture infectious
dose 50 (TCID50) per ml. For prime only studies a serum sample
was taken ten days post-vaccination to measure neutralizing
antibodies. For studies with prime and boost serum samples were
collected on days 28 and 42 post-primary vaccination. Neutral-
ization titers were determined using a TCID50 based assay that
was modified from Grosfeld et al. [65]. Briefly, sera were
incubated at 56uC for 60 min to inactivate complement and then
serially diluted two-fold starting at a dilution of 1 in 5. Dilutions
were performed in DMEM as described above except containing
only 2% FBS. Subsequently, 100 TCID50 units of CHIKV were
added to each well in the same dilution media. The virus/serum
mixture was then incubated at 37uC for 1 hr. Following
incubation, 100 mL of the mixture was added to 96 well plates
seeded with Vero cells and monitored for 3–4 days for presence of
cytopathic effects (CPE).
Flow cytometric analysis of T cell responses
T cell responses were analyzed as previously described [50,53].
Briefly, A129 mice were euthanized 2 weeks post-boost. After red
blood cell (RBC) lysis, single-splenocyte suspensions were resus-
pended in RPMI-1640 medium supplemented with 10% FBS 16
penicillin/streptomycin and 0.14 mM of b-mercaptoethanol.
Splenocytes were stimulated with three CHIKV peptide pools
that cover the entire protein sequences of E3, E2 and NSP2,
respectively. The peptide pools were used at a concentration of
1 mg/well separately in 200 mL total volume for 16 h in the
presence of Brefeldin A. Peptide pools were a generous gift from
Dr. Daniel Streblow [66] and were synthesized by Thermo Fisher
Scientific. Cells were stained intracellularly for IFN-c APC
(XMG1.2), IL-2 PE (JES6-5H4), TNF-a PE (MP6-XT22) and
CD40L (MR1) after surface staining of CD4 FITC (RM4-5) or
anti-mouse CD8a PerCP (53–6.7). The samples were acquired on
a BD FACSCalibur and analyzed with FlowJo v7.6.5 (Tree Star).
Statistical analysis
GraphPad Prism 6 software (La Jolla, CA) was used for all
statistical analyses. Statistical analysis of viremia levels were
performed using an unpaired T-test with Welch’s correction for
unequal variance. Survival analysis was performed to assess
vaccine effectiveness against; reported P-values are from the
Mantel-Cox test.
Results
Characterization of MVA-CHIK recombinant vaccine: PCR
analysis, protein expression and cellular localization
Genetic homogeneity of final virus constructs was analyzed by
PCR. Purified viral DNA was used as a template for amplification
by primers specific for the flanking regions of deletion III. The
presence of E3/E2 was confirmed in MVA-CHIK by a band at
the expected size of roughly 3 kb (Fig. 1b) which indicated the
maintenance of the insertion throughout plaque selection. MVA-
GFP (,1500 bp) and wild-type MVA (657 bp) were included as
controls. In addition, DNA sequencing confirmed that no genetic
alterations were present in the final construct (data not shown).
The expression of p62 antigen by the MVA-CHIK recombinant
viruses and wild-type CHIKV was monitored by immunoblot
analysis. Cell pellet lysates and supernatants from infected CEFs
were tested for protein expression (Fig. 1c). The p62 (62 kD)
protein was detected at 24 hr p.i. in both wild-type CHIKV and
MVA-CHIK infected cells, but not in MVA-GFP or mock
infected cells. Interestingly, a cleaved E2 protein (,50 kD) was
detected in wild-type infected cells, but not in the MVA-CHIK
lysates, suggesting the lack of furin cleavage and release of the E3
peptide from the p62 precursor protein. Expression of E2 was
observed in the supernatant of CHIKV infected cells, but there
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Figure 2. MVA-CHIK candidate vaccine protected A129 mice against CHIK-LR challenge. A129 mice were vaccinated with either prime
alone or a prime and boost (day 28) of each vaccine virus (107 TCID50 units of MVA-CHIK or MVA-GFP, or 10
4 TCID50 units of CHIK-IRES). Mice were
then challenged with 102 TCID50 units of wild-type CHIKV intradermally (in the hind left footpad) eleven days post-prime or two weeks post-boost.
Prior to boost (where applicable) and challenge, mice were bled and serum was monitored for both total Ig(G+M) and neutralizing activity by TCID50
MVA Vectored Vaccine Protects Mice against Chikungunya Virus
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was no detection of E2 expression in MVA-CHIK, suggesting that
the protein was not being secreted.
To determine the cellular localization of CHIKV proteins,
MVA-CHIK infected cells were fixed and then probed for
production of CHIKV E3/E2 proteins using polyclonal serum.
In order to determine if the E2 protein was reaching the surface of
the cells, a single cell set was permeabilized while the other set
remained intact. Permeabilized cells stained much brighter than
those that were not (Fig. 1d). This indicated that CHIKV E3/E2
proteins were being maintained inside the cell and not reaching
the cell surface as is observed with wild-type CHIKV infection.
Immunogenicity and protection in A129 mice
To evaluate the protective efficacy of the MVA-CHIK vaccine,
an active immunization study was conducted in A129 mice. This
mouse strain is more sensitive to CHIKV infection and experience
high viremia, footpad swelling and succumb to infection [51]
compared to immunocompetent strains of mice. Mice were
vaccinated as described previously and then challenged with wt-
CHIKV. MVA-CHIK or MVA-GFP vaccinated mice had
background levels of neutralizing antibodies, whereas all CHIK-
IRES vaccinated mice seroconverted (Fig. 2a). Serum collected
from these mice post-prime and post-boost was tested for total
anti-virus Ig(G+M) antibodies by ELISA. A clear booster effect
was seen in MVA-CHIK vaccinated mice, as the differences
between post-prime and post-boost samples were highly significant
(p,0.001) (Fig. 2b). This difference was not as profound with
CHIK-IRES vaccinated mice as they had high levels of anti-virus
antibodies even prior to boost. MVA-CHIK and CHIK-IRES
groups were protected 100% from lethal challenge after prime and
boost (Fig. 2c). In addition, MVA-CHIK mice were completely
protected against both viremia and footpad swelling (Figs. 2d–e).
Next, we compared by histopathology the footpads of MVA-
CHIK and MVA-GFP vaccinated A129 mice. Vaccinated mice
were challenged in the same way described above and subse-
quently were euthanized seven d.p.i. to assess local tissue damage.
Following infection, footpads from MVA-CHIK vaccinated mice
displayed mild inflammation with limited muscle damage (Fig. 3a).
In contrast, footpads from MVA-GFP mice exhibited severe
necrotic muscle degeneration with edema, consistent with previous
reports from unvaccinated mice (Fig. 3b) [47,67].
Immunogenicity and protection in BALB/c mice
The immunocompetent BALB/c mouse model was selected to
evaluate the immunogenicity of MVA-CHIK as it has been used
previously with MVA and CHIKV [37,53,68]. Following vacci-
nation, low levels of neutralizing antibodies were detected in mice
immunized with MVA-CHIK (Fig. 4a). Immunized mice were
then challenged with wild-type CHIKV to determine protection
against viremia. Viremia was not detected in any of the MVA-
CHIK vaccinated mice (n = 6) (Fig. 4b). In contrast, all MVA-GFP
immunized mice had significant levels of viremia (p= 0.027).
Passive transfer of immune serum
To determine whether antibodies present in BALB/c (Avg.
neut. titer of 9.2) or A129 (undetectable neut. titer) vaccinated
mice were sufficient for protection against CHIKV, pooled
immune serum was passively transferred into naı¨ve A129 mice.
As a positive control, an additional group of mice was treated in
the same manner with a pool of serum (avg. neut. titer of 64) from
A129 mice vaccinated with CHIK-IRES candidate vaccine. All of
the mice treated with either anti-MVA-CHIK or MVA-GFP
immune serum had high levels of viremia and succumbed to
infection (Fig. 4c–d). Viremia in mice passively transferred serum
from MVA-CHIK vaccinated A129 was slightly reduced on day 2
post-infection, however this was not significant (p = 0.11). In
contrast, CHIK-IRES immune serum provided full protection
against viremia and mortality (Figs. 4c–d).
MVA-CHIK immune CD4+ T cells are indispensable for
protection in the A129 model
To determine the role of T cells in protection we first
investigated whether MVA-CHIK could elicit a T cell response
in A129 mice by measuring cytokine production. Upon in vitro re-
stimulation with a CHIKV peptide pool that covers the protein
sequence of E2, MVA-CHIK immune CD4+ T cells produced the
cytokine IFNc and upregulated co-stimulatory molecule CD40L at
significantly higher levels as compared to MVA-GFP vector
control (p = 0.02 and 0.01, respectively) (Fig. 5a–b). No response
was observed when MVA-CHIK splenocytes were stimulated with
peptide pools against either E3 or NSP2 (viral protein negative
control) (Fig. 5c–d), suggesting the immune response is specific to
E2. In addition, there were no significant differences in other
cytokines monitored, including TNFa, IL-2, IL-4, IL-6, IL-10, and
Il-17a (data not shown). Furthermore, none of the cytokines tested
showed a difference between the two groups in immune CD8+ T
cells (data not shown). Similar results were obtained when MVA-
CHIK immune splenocytes were stimulated with live or inacti-
vated whole virus preparations (data not shown).
To test whether MVA-CHIK-specific immune CD4+ or CD8+
T cells were indeed protective, we depleted CD4+ or CD8+ T cells
from vaccinated mice prior to challenge with wt-CHIKV. Mice
depleted of CD8+ T cells or control non-depleted mice had no
footpad swelling and survived the challenge (Fig. 6a–b). In
contrast, CD4+ depleted mice along with MVA-GFP controls
succumbed to infection (Fig. 6b). Mice depleted of CD4+ T cells
also had high levels of viremia and footpad swelling, similar to the
MVA-GFP controls (Fig. 6a–c). Interestingly, CD8+ T cell
depleted vaccinated mice remained healthy without footpad
swelling throughout the duration of the study despite developing
a low level of viremia three d.p.i.
Discussion
The recent re-emergence of CHIKV has resulted in several
explosive outbreaks and underscores the need for an effective
vaccine. Several groups have recently employed varying strategies
to construct effective vaccines against CHIKV. Live-attenuated,
inactivated, adenovirus vectored, DNA, and VLP based strategies
all have been tested and have been shown to be effective in
providing protection against CHIKV [12,13,68,69]. Despite
promising results, these vaccine candidates all have some
drawbacks. Safety, stability, and production of a broad long-lived
immune response are necessary for any effective vaccine. Safety
concerns remain for both live-attenuated and adenovirus based
approaches. Inactivated and VLP based approaches require
adjuvants and normally elicit weak T cell responses. In contrast,
MVA has been shown to be safe in thousands of human patients
micro-neutralization assay (A) and ELISA (B), respectively. Prime only MVA-GFP data is not shown because it does not differ with the prime & boost
groups. Mice were monitored for 14 days following challenge for survival (C) and footpad swelling (D). The first three days following challenge
viremia levels were measured via TCID50 (E). The dotted line indicates the limit of detection of the assay.
doi:10.1371/journal.pntd.0002970.g002
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and also in every animal tested [21,22,58]. Furthermore, mice
deficient in a/b/c interferon signaling experienced no clinical
symptoms following vaccination with MVA-CHIK (data not
shown) and we have previously shown other MVA constructs to be
safe in highly immunodeficient SCID mice [37]. In addition, the
stability of poxviruses and MVA’s ability to be lyophilized are
optimal for use in developing countries where the vaccine is
needed most and cold-chains cannot be reliably maintained. MVA
also has been shown to stimulate a broad immune response,
including the induction of cellular immunity [62,70].
Here, we describe the construction, expression, and preclinical
efficacy and safety of a novel MVA-CHIK vaccine candidate.
BALB/c mice, which are immunocompetent, were 100%
protected from viremia upon challenge. A129 mice, which are
deficient in a/b interferon signaling, and therefore highly
susceptible to CHIKV infection, were also completely protected
against challenge with wtCHIKV after prime and boost vaccina-
tions. In addition, 80% of mice were protected from lethal
challenge following prime only vaccination with MVA-CHIK.
Despite the robust protection observed, mice did not produce a
strong neutralizing antibody response following vaccination.
Although vaccinated A129 mice developed undetectable levels of
neutralizing antibodies, they did produce a significant amount of
anti-virus antibodies, which for other alphaviruses have been
shown to be protective [71–73]. A129 mice passively transferred
MVA-CHIK immune serum from either BALB/c or A129 mice
were not protected against mortality, or footpad swelling following
challenge, despite a slight reduction in viremia 2 days post-
infection in mice transferred A129 MVA-CHIK immune serum
(p = 0.11). This suggests antibodies induced by vaccination were
not sufficient to provide protection in this manner. This could be
due to the fact that passively administered immune serum is
significantly diluted in the circulation of naı¨ve mice. Further
evidence that antibodies are not sufficient for protection alone was
provided by depletion studies conducted in MVA-CHIK vacci-
nated mice. When immune CD4+ T-cells were depleted, despite
the presence of full levels of circulating anti-virus antibodies, mice
were 100% susceptible to lethal infection. If anti-virus antibodies
were essential for protection a reduction in mortality or viremia
would be expected in the CD4+ depleted mice, which was not
observed. These data suggest that MVA-CHIK is providing
protection by a novel mechanism that is not based solely on
vaccine induced serum circulating antibodies.
While antibodies do not protect via passive transfer or during
depletion, it remains unclear what role they may be playing during
infection of an MVA-CHIK immunized mouse. Immunocyto-
chemistry and western blot analysis suggested CHIKV p62 protein
was being maintained inside of the cell and that furin cleavage was
not occurring to separate E3 from E2, respectively. P62 was
chosen due the presence of immunodominant epitopes and the
fact that previous reports have shown that it could be an effective
immunogen against other alphaviruses [71,74]. In addition, it has
been previously observed that when expressed by a plasmid, the
presence of E1 is not a requirement to allow E2 to be placed on
the outside of the plasma membrane [75,76]. Barth et al. (1997)
also demonstrated that in the context of an E1 deleted Semliki
Forest virus, p62 is not transported efficiently to the plasma
membrane while E2 alone is [77]. Therefore, absence of E2 on the
surface of infected cells is not completely unexpected and may
have proven to be serendipitous in allowing the production of a
more robust CD4+ immune response. This could provide an
explanation for the lack of a strong humoral immune response, as
antibodies would have limited access to this intracellular protein.
In addition, an improperly folded protein would be expected to
produce many virus binding antibodies but few that are
neutralizing, which our data suggest. A recent report by Metz et
al. (2013), suggested that E2 produced in combination with E1 in a
baculovirus system is more immunogenic (i.e., produces higher
neutralizing antibodies) than either protein alone [78]. This might
suggest that E1 and E2 are more efficient together to obtain a
robust neutralizing antibody response and might explain why
MVA-CHIK produces few neutralizing antibodies.
Analysis of ex vivo cellular responses indicated that MVA-
CHIK induced antigen-specific CD4+ T cells but not CD8+ T
cells, suggesting that immune CD4+ T cells are the main effector
cells. This is supported by the cellular depletion studies that
showed the protective role of CD4+ T-cells. T-cell mediated
protection has previously been demonstrated with another
alphavirus, VEEV [79]. Yun et al. (2009) were able to adoptively
transfer CD4+ T-cells and obtain protection after multiple
immunizations, where passive transfer of hyper-immune serum
was not protective. Interestingly, they did not observe a difference
in viral titers in the brain from surviving mice, while MVA-CHIK
vaccination completely protected against viremia in our studies.
Recent studies based on another vaccine candidate, CHIK-
IRES, have shown that a correlate of protection based on
antibodies can be established for CHIKV [50]. Herein, we present
data that suggest that this is specific to the vaccine being used and
that there may be more than one way to provide protection against
CHIKV. MVA-CHIK selectively expresses E2-E3 proteins. It
could be argued that the processing of this virus is substantially
different than the live attenuated CHIK-IRES vaccine or wild-
type CHIKV. As a result, during infection a different set of
epitopes are generated that may well be protective via alternative
mechanisms. In another report, using mice deficient in either B-
cells or CD4+ T cells, data were presented that suggested that
antibodies are essential in controlling CHIKV infection and that
CD4+ T cells may exacerbate disease [49,80]. Hawman et al.
(2013) found similarly, that mice deficient in both B and T-cells
had less severe tissue pathology early after CHIKV infection when
compared to wild-type controls [81]. However, in the same report
it was demonstrated that virus was inefficiently cleared in the
absence of lymphocytes, suggesting a possible dual role for these
cells during early CHIKV infection where some tissue damage is
allowed in order to control viral dissemination. While we observe
very little evidence of tissue damage in vaccinated mice, it is
possible that MVA-CHIK induced specific CD4+ T-cells which
are able to effectively control viral replication while minimizing
collateral tissue injury. It remains possible that CD4 T-cells are
required for recall responses to produce antibodies following
challenge, although this is unlikely as mice would be expected to
have early viremia, which we did not observe in vaccinated mice
(Fig. 2E). Currently, we are conducting studies to determine the
role of CD4+ T cells in protection. Our data are also contrary to
the previous report by Teo et al. (2013), where no footpad swelling
was observed upon antibody depletion of CD4+ T cells during
Figure 3. MVA-CHIK vaccine protects against local inflammation following CHIK-LR challenge. 7 d.p.i, A129 mice were sacrificed and
hind limbs were harvested, fixed, decalcified and processed for staining with Hematoxylin and eosin (H&E). MVA-CHIK vaccinated mice showed low
levels of inflammation (A) upon infection with 102 TCID50 units of wild-type CHIKV. MVA-GFP vaccinated mice developed massive inflammation with
necrotic muscle degeneration and edema following challenge (B).
doi:10.1371/journal.pntd.0002970.g003
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CHIKV infection [80]. However, their studies were performed in
naı¨ve mice with a functional interferon system, in contrast, our
studies used vaccinated mice without proper IFN a/b signaling,
and thus might account for the differences observed. Additionally,
recent studies in humans show that there is a strong CD4+ IFNc
positive T-cell response directed against the E2 protein, suggesting
it might be playing a role in the protective immune response
against the virus [82]. Therefore, the data presented here may be
relevant to human infection, and suggest that antibodies may not
be the only mediator of protection against alphaviruses.
A recently published report by Garcia-Arriaza et al. (2014) also
has used MVA as a vector as a CHIKV vaccine candidate [83].
Their vaccine, which expressed the entire structural protein is
effective at inducing a high level neutralizing antibody response
accompanied by a strong CD8+ T-cell specific cell mediated
response, in direct contrast to the results reported here. They
report that the E2 protein can be found in both the plasma
membrane and the cytoplasm, in contrast to our results which
clearly showed E2 is not on the surface of the cell (Figure 1). This
could explain why the immune responses are so drastically
different between the two vaccine candidates. While depletion
studies indicated CD4+ T cells are indispensable for protection for
MVA-CHIK in this report, the mechanism of protection is unclear
in their report, although high levels of neutralizing antibodies
Figure 4. MVA-CHIK candidate vaccine fully protects BALB/c mice against CHIKV viremia. BALB/c mice were vaccinated with a prime and
boost (day 28) of 107 TCID50 units of MVA-CHIK vaccine virus and then challenged with 10
4 TCID50 units of wild-type CHIKV intradermally (in the hind
left footpad) two weeks post-boost. Prior to challenge, BALB/c mice were bled and serum was monitored for neutralizing activity by TCID50 micro-
neutralization assay (A). Mice were bled two days following challenge and viremia levels were measured via TCID50 (B). For passive immunization,
prime and boost vaccinated BALB/c and A129 mice were bled and serum taken from each mouse was pooled with equal volumes into separate pools
from each strain. Pools of serum (100 mL for BALB/c and 200 mL for A129) were then injected i.p. into A129 mice which were challenged 24 hrs later
with 102 TCID50 units of wild-type CHIKV. Viremia was measured 2 d.p.i (C) and survival was monitored for two weeks post-challenge (D). The dotted
line indicates the limit of detection of the assay.
doi:10.1371/journal.pntd.0002970.g004
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Figure 5. MVA-CHIK elicited a CHIK-E2-specific CD4+ T cell response in A129 mice. Two weeks following boost, splenocytes from MVA-GFP
or MVA-CHIK immunized mice were stimulated with CHIKV NSP2, E2 or E3 peptide pools (1 mg/well). T-cells were then stained for intracellular IFNc (A
and C) or CD40L (B and D). Representative dot plots (for only one mouse per group) are shown for both cytokines with MVA-CHIK and MVA-GFP
stimulated with E2 peptide pools or background media control (A and B). For stimulation with E2, E3 and NSP2 peptide pools data are presented as
the mean+SD of the percentages cytokine-positive cells among gated CD4+ T cells (3 mice/group) with background subtracted (C and D). Stimulation
was significantly higher for IFNc and CD40L in the MVA-CHIK immune group, as compared to MVA-GFP control (p = 0.02 and p= 0.01, respectively).
No cytokine production in CD8+ T cells was observed (data not shown).
doi:10.1371/journal.pntd.0002970.g005
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Figure 6. Depletion of MVA-CHIK immune CD4+ T cells, but not CD8+ T cells, abolished the protective immunity afforded by MVA-
CHIK in A129 mice. A129 mice were depleted of CD4+ or CD8+ T cells with anti-CD4 or CD8 mAbs and were then challenged with 500 TCID50 units
of CHIK-LR i.d. via the left hind footpad on day 14 post boost. Mice were monitored for (A) footpad swelling; (B) survival and (C) Viremia (measured
2 d.p.i by TCID50 assay). The dotted line indicates the limit of detection of the assay.
doi:10.1371/journal.pntd.0002970.g006
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induced by their vaccine are likely protective [50]. Additionally,
the vaccine constructed by Garcia-Arriaza et al. (2014) uses the
entire structural protein consisting of Capsid-E3-E2-6K-E1. In
contrast, our vaccine contains only the E3-E2 portion. Recent
reports have shown that the capsid protein contains immunodo-
minant epitopes for both B and T cells [55,82], and was therefore
excluded from our vaccine construct in favor of E2 with its
accessory protein E3. Furthermore, we used a footpad injection
which more closely mimics intradermal vaccination a human
might be expected to receive. Garcia-Arriaza et al. (2014) used
intraperitoneal vaccinations, which are not given to humans and
therefore could potentially induce a vastly different immune
response delivered by another route.
In conclusion, these studies demonstrate the potential of MVA
to effectively express CHIKV E3-E2 proteins and generate
protective immune responses despite the presence of low or absent
neutralizing antibody responses. The MVA construct expressing
CHIKV p62 protein was effective in several mouse models and
provided protection against two critical markers of disease, viremia
and joint swelling. The vaccine was protective despite low levels of
neutralizing antibodies which are normally considered to be the
golden standard for protection against alphaviruses. Therefore the
results reported here challenge the assumption that only these
antibodies are effective in providing protection against CHIKV or
other alphaviruses. Future studies combining a T-cell targeted
vaccine, like the one presented here, along with a more traditional
vaccine which induces strong neutralizing antibodies could
provide a more robust and comprehensive immune response in
a safe and easy to deliver vaccine regimen. However, further work
is required to characterize the protective mechanisms it provides.
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